Drug-pricing dispute at US Supreme Court raises trade secret disclosure questions
By Steve Scherer ( June 24, 2026, 22:00 GMT | Comment) -- The US Supreme Court on Monday asked the federal government to weigh in on a challenge to Oregon’s drug-pricing transparency law in a case presenting broader questions about constitutional limits on state efforts to compel disclosure of trade secrets across regulated sectors.The US Supreme Court on Monday invited the federal government to weigh in on a pharmaceutical industry's challenge to an Oregon drug-pricing transparency law, a dispute whose impact could extend beyond the drug companies if the bench decides to rule on the limits of compelled disclosure of confidential business information, legal experts said....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.